Navigation Links
New test discovered to better predict breast cancer outcomes
Date:1/27/2011

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Research Institute of the McGill University Health Centre (RI MUHC), the DanaFarber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

For years, clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach. Some cancers respond to specific treatments while others do not. Close to 50 per cent of breast cancer patients belong to a group defined as "estrogen receptor positive/lymph node negative (ER+/LR-)" that is at low risk of relapse. The majority of patients in this group may not require any treatment beyond the surgical removal of their tumour, while a small minority should receive additional treatment.

"The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favour of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments," explains Dr. Alain Nepveu, GCRC and RI MUHC researcher and co-author of the study. "Since many treatments are associated with short- and long-term complications including premature menopause, cardiotoxicity and the development of secondary cancers, risks must be balanced against the potential benefit for each patient to avoid unnecessary suffering, needless expense and added burdens on the health-care system."

While more research is required before the test would be ready for market and incorporated into existing diagnostic procedures, Nepveu suggests it has the potential to be commercialized within five years.


'/>"/>

Contact: Allison Flynn
allison.j.flynn@mcgill.ca
514-972-3934
McGill University
Source:Eurekalert

Page: 1

Related medicine news :

1. First Gene Variants Linked to Stuttering Discovered
2. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
3. Genes Behind Tooth Development Discovered
4. Genetic cause discovered for rare bleeding disorder
5. Gene discovered for newly recognized disease in Amish children
6. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
7. Genetic pattern that predicts leukemia relapse discovered
8. Researchers report new autism genes discovered
9. New function discovered in cancer-prevention protein
10. New strain of bacteria discovered that could aid in oil spill, other environmental cleanup
11. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned ... Texas, is launching a cooperative charity drive with the Tarrant Area Food Bank in ... 50,000 individuals and families in need, the Tarrant County Food Bank offers hope and ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... The primary goal of this research is to analyze ... of liquid biopsy. Key information the survey seeks to ... liquid biopsy adoption amidst future users - Predominantly used ... Sample inflow to conduct liquid biopsy tests - Preference ... on. - Correlation analysis of sample type and biomarker ...
Breaking Medicine Technology: